CURRICULUM VITAE
Gang Cheng PhD
Gang Cheng PhD
Assistant Professor
Department of Biophysics
Department of Biophysics
OFFICE ADDRESS: |
8701 Watertown Plank Road |
Milwaukee, WI 53226 |
EDUCATION: |
09/1995 - 07/1999 BS in pharmacy, Shandong University, Shandong, China |
09/1999 - 07/2002 MS in pharmacology, Shenyang Pharmaceutical University, Shenyang, China |
09/2002 - 12/2005 PhD in pharmacology, Shenyang Pharmaceutical University, Shenyang, China |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
01/2006 - 04/2008 Postdoctoral Fellow, Beijing Institute of Pharmacology and Toxicology, Beijing, China |
07/2008 - 07/2009 Postdoctoral Fellow, Department of Pathology & Lab Medicine, University of Rochester Medical Center, Rochester, NY |
08/2009 - 07/2011 Postdoctoral Fellow, Department of Biophysics, Medical College of Wisconsin, Milwaukee, WI |
FACULTY APPOINTMENTS: |
2021 - Present Assistant Professor, Biophysics, Medical College of Wisconsin, Milwaukee, WI |
AWARDS AND HONORS: |
2005 Outstanding Oral Presentation, Chinese Young Researchers’ Symposium on Pharmacology, National Pharmacology Conference & Chinese Young Researchers’ Symposium on Pharmacology, China Xi’an |
2010 Seahorse Bioscience Travel Grant, awarded for travel to for Free Radical Biology and Medicine’s 17th Annual Meeting, Orlando, FL, USA |
2011 Seahorse Bioscience Travel Grant, awarded for travel to for Free Radical Biology and Medicine’s 18th Annual Meeting, Atlanta, GA, USA |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
2005 - 2006 Member of the Asian Society for Vascular Biology |
2005 - 2008 Member of the Chinese Society for Pharmacology |
2010 - Present Society for Free Radical Biological and Medicine |
2011 - Present American Association for Cancer Research |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Journal Review |
2011 - Present Free Radical Biology & Medicine |
2012 - Present Frontiers in Oxidant Physiology |
2012 - Present Nitric Oxide |
2012 - Present Molecular Carcinogenesis |
2013 - Present Acta Pharmacologica Sinica |
2016 - Present Oxidative Medicine and Cellular Longevity |
2017 - Present Scientific Reports |
2018 - Present Redox Biology |
2018 - Present Phytomedicine |
2019 - Present BBA - General Subjects |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PEER REVIEWED WORKSHOPS/PRESENTATIONS: |
National |
Joy Joseph, Jin-Hwan Kim, Gang Cheng, Jacek Zielonka, Balaraman Kalyanaraman, Enhanced Antiproliferative and Cytotoxic Effects of Mitochondria-Targeted Tocopherol in Breast Cancer Cells, Society for Free Radical Biological and Medicine (SFRBM) 17th Annual Meeting, Orlando, FL, 11/2010 |
Gang Cheng, Jacek Zielonka, Joy Joseph, Balaraman Kalyanaraman, Synergistic Inhibition of Bioenergetic Pathways in Pancreatic Cancer Cells by Mitochondria-Targeted Nitroxide and Glycolytic Inhibitors, American Association for Cancer Research Annual Meeting, Chicago, IL, 03/31/2012 - 04/04/2012 |
Gang Cheng, Jacek Zielonka, Alexander R Dayton, Joy Joseph, Balaraman, Kalyanaraman, Alterations in Kreb’s Cycle Carbon Pool and Bioenergetics Metabolites in Pancreatic Cancer Cells Treated with Mitochondria-Targeted Drug, Society for Free Radical Biological and Medicine (SFRBM) 19th Annual Meeting, 11/2012 |
Gang Cheng, Jacek Zielonka, Joy Joseph, Balaraman Kalyanaraman, Synergistic Lethality of Inhibitors of Bioenergetic Pathways in Pancreatic Cells, Society for Free Radical Biological and Medicine (SFRBM) 18th Annual Meeting, Atlanta, GA, 11/2012 |
Gang Cheng, Jacek Zielonka, Balaraman Kalyanaraman, Modulatory Effects of MitoSOX On Cellular Bioenergetics: a Cautionary Note, Society for Free Radical Biological and Medicine (SFRBM) 18th Annual Meeting, Atlanta, GA, 11/2012 |
Jacek Zielonka, Gang Cheng, Jin-Hwan Kim, Joy Joseph, Balaraman Kalyanaraman, Selective Killing of Breast Cancer Cells by Mitochondria-Targeted α-Tocopherol, Society for Free Radical Biological and Medicine (SFRBM) 18th Annual Meeting, Atlanta, GA, 11/2012 |
Gang Cheng, Donna McAllister, Jacek Zielonka, Brian P. Dranka, Joy Joseph, Balaraman Kalyanaraman, Synergistic Enhancement of 2-Deoxy-D-Glucose-Mediated Breast Cancer Cell Death by Mitochondria-Targeted Drugs, Society for Free Radical Biological and Medicine (SFRBM) 18th Annual Meeting, Atlanta, GA, 11/2012 |
High-Throughput Screening (HTS) Assay for Identifying Potent and Selective Small-Molecule Inhibitors of NADPH Oxidases, Society for Free Radical Biological and Medicine (SFRBM) 19th Annual Meeting, 11/2012 |
A Dilip, G Cheng, J Joseph, B Kalyanaraman, TC Gamblin, Mitochondria-Targeted Antioxidant and Glycolysis Inhibition? Synergistic Therapy in Hepatocellular Carcinoma, Academic Surgical Congress - 8th Annual Meeting, New Orleans, LA, 02/05/2013 - 02/07/2013 |
Gang Cheng, Jacek Zielonka, Joy Joseph, Balaraman Kalyanaraman, Bioenergetic Changes in Glycolysis, Kreb’s Cycle, and Tlutaminolysis in Pancreatic Cells Treated with Mitochondria-Targeted Cationic Drugs, American Association for Cancer Research Annual Meeting, Washington DC, 04/06/2013 - 04/10/2013 |
Gopitkumar Shah, Bryan Sack, Gang Cheng, Jacek Zielonka, Balaraman Kalyanaraman, William See, BCG-Induced Depletion of Intracellular ATP in Human Urothelial Carcinoma Cell Lines Correlates with Cellular Injury and Cytotoxicity, American Urological Association (AUA) Annual Meeting, San Diego, CA, 05/04/2013 - 05/08/2013 |
Guangjian Zhang, Fanghong Chen, Yanli Cao, Jacek Zielonka, Gang Cheng, Gopit Shah, Balaraman Kalyanaraman, William See, Loss of BCG Viability Adversely Affects the Direct Response of Urothelial Carcinoma Cells to BCG Exposure, American Urological Association (AUA) Annual Meeting, San Diego, CA, 05/04/2013 |
Regional |
Gang Cheng, Jacek Zielonka, Brian P. Dranka, Joy Joseph, Balaraman Kalyanaraman, Uptake, Subcellular Localization, Bioenergetic Effects and Antiproliferative Properties of Triphenylphosphonium Linked Nitroxides in Breast Cancer Cells, Society for Free Radical Biological and Medicine (SFRBM) 17th Annual Meeting, Orlando, FL, 11/2010 |
PATENTS: |
11/03/2005 World Intellectual Property Organization patentWO2005103046 (A1) (also published as PCT/CN2005/000153) (issued November 3, 2005); "Selenophen derivatives and the use of preventing and/or treating the diseases relating to protein aging thereof" Inventors: Li S, Zhong W, Wang L, Cheng G, Liu H, Ruan C, Cui H, Xiao J, Zheng Z, Xie Y, Hu Y, Nie A |
03/30/2006 World Intellectual Property Organization Patent No. WO2006032165(A1) (also published as PCT/CN2004/001082 ) (issued March 30, 2006); "Novel substituted 5-membered-N-heterocyclic compounds and the use of them in treatment of the diseases associated with the aging of proteins" Inventors: Li S, Cui H, Wang L, Cheng G, Zhong W, Nie A, Liu H, Hu Y, Xiao J, Zheng Z |
04/06/2006 World Intellectual Property Organization Patent No. WO2006034605(A1) (also published as PCT/CN2004/001119) (issued April 6, 2006; "Novel azabicyclic ring ammoniums and their use for treating protein aging disease" Inventors: Li S, Cui H, Wang L, Cheng G, Zhong W, Nie A, Liu H, Hu Y, Xiao J |
09/21/2010 U.S. Patent No. 7799813 B2 (also published as PCT/CN2007/000319) (issued September 21, 2010); "Salts of substituted 5-membered azacycle and use thereof in the treatment of diseases related to protein aging" Inventors: Li S, Cui H, Xiao J, Zhong W, Wang L, Cheng G |
06/27/2012 European Patent No. EP 1 985 296 B1 (also published as: PCT/CN2007/000319, WO 2007/085203) (issued July 27, 2012); "New substituted pentabasic azaheterocyclic compounds and its use of treating protein aging disease" Inventors: Li S, Cui H, Xiao J, Zhong W, Wang L, Cheng G |
11/25/2012 U.S. Patent No. 8338616 B2 (also published as PCT/CN2009/001036, WO 2010/031248) (issued November 25, 2012); "Thiazoliums and their use for treating protein aging associated diseases" Inventors: Li S, Zhong W, Wang L, Zheng Z, Cui H, Xiao J, Cheng G, Xie Y, Zhang B |
08/10/2021 U.S. Patent No. 11,083,739 (issued August 10, 2021) / MCW Tech ID: C1999; "Mito-magnolol compounds and methods of synthesis and use thereof” Inventors: Balaraman Kalyanaraman, Jacek M. Zielonka, Gang Cheng, Micael J. Hardy, Olivier Ouari
|
03/28/2023 U.S. Patent No. 11,612,610 (issued Mach 28, 2023) / MCW Tech ID: C1999; “Mito-magnolol compounds and methods of synthesis and use thereof” Inventors: Balaraman Kalyanaraman, Jacek M. Zielonka, Gang Cheng, Micael J. Hardy, Olivier Ouari
|
WORK EXPERIENCE: |
2011 - 2016 Research Scientist, Department of Biophysics, Medical College of Wisconsin, Milwaukee, WI |
2016 - 2021 Present Research Scientist II, Department of Biophysics, Medical College of Wisconsin, Milwaukee, WI |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Xu P-P, Cheng G , Zhou X-M, Ma T, Xu C, Cao Y-L, Su L. Effects of piracetam on the content of monoamines transmitter induced by restraint water-immersion in the rat brain Journal of Shenyang Pharmaceutical University. 2001,18(5):366-9 [in Chinese]. |
2. Cheng G, Wang L-L, Long L, Cao Y-L, Li S. Cardiovascular effects of advanced glycation endproducts breaker (C24) in diabetic rats Journal of Shenyang Pharmaceutical University. 2006, 23(7):452-5 [in Chinese]. |
3. Zhang B, Cheng G, Wang L-L, Li S. AGEs cross-links and endothelium dysfunction Chinese Pharmacological Bulletin. 2007, 23(5):565-7 [in Chinese]. |
4. Tang HL, Wang LL, Cheng G, Wang L, Li S. Evaluation of the cardiovascular function of older adult Rhesus monkeys by ultrasonography. J Med Primatol. 2008 Apr;37(2):101-8. |
5. Zhang B, Cheng G, Liu H, Wang L-L, Li S. Establishment of a diabetic-hypertensive rat model Journal of Shenyang Pharmaceutical University. 2009, 23(7):452-5 [in Chinese]. |
6. Cheng G, Wang LL, Qu WS, Long L, Cui H, Liu HY, Cao YL, Li S. C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats. Acta Pharmacol Sin. 2005 Dec;26(12):1460-6. |
7. Cheng G, Lopez M, Zielonka J, Hauser AD, Joseph J, McAllister D, Rowe JJ, Sugg SL, Williams CL, Kalyanaraman B. Mitochondria-targeted nitroxides exacerbate fluvastatin-mediated cytostatic and cytotoxic effects in breast cancer cells. Cancer Biol Ther. 2011 Oct 15;12(8):707-17. PMCID: PMC3218525 |
8. Cheng G, Zielonka J, Dranka BP, McAllister D, Mackinnon AC Jr, Joseph J, Kalyanaraman B. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res. 2012 May 15;72(10):2634-44. PMCID: PMC3700358 |
9. Cheng G, Zielonka J, McAllister DM, Mackinnon AC Jr, Joseph J, Dwinell MB, Kalyanaraman B. Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. BMC Cancer. 2013 Jun 13;13:285. PMCID: PMC3686663 |
10. Dickey JS, Gonzalez Y, Aryal B, Mog S, Nakamura AJ, Redon CE, Baxa U, Rosen E, Cheng G, Zielonka J, Parekh P, Mason KP, Joseph J, Kalyanaraman B, Bonner W, Herman E, Shacter E, Rao VA. Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model. PLoS One. 2013;8(8):e70575. PMCID: PMC3734284 |
11. Dilip A, Cheng G, Joseph J, Kunnimalaiyaan S, Kalyanaraman B, Kunnimalaiyaan M, Gamblin TC. Mitochondria-targeted antioxidant and glycolysis inhibition: synergistic therapy in hepatocellular carcinoma. Anticancer Drugs. 2013 Oct;24(9):881-8. PMCID: PMC4028966 |
12. Cheng G, Zielonka J, McAllister D, Tsai S, Dwinell MB, Kalyanaraman B. Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. Br J Cancer. 2014 Jul 08;111(1):85-93. PMCID: PMC4090735 |
13. Zielonka J, Cheng G, Zielonka M, Ganesh T, Sun A, Joseph J, Michalski R, O'Brien WJ, Lambeth JD, Kalyanaraman B. High-throughput assays for superoxide and hydrogen peroxide: design of a screening workflow to identify inhibitors of NADPH oxidases. J Biol Chem. 2014 Jun 06;289(23):16176-89. PMCID: PMC4047388 |
14. Cheng G, Zielonka J, McAllister D, Hardy M, Ouari O, Joseph J, Dwinell MB, Kalyanaraman B. Antiproliferative effects of mitochondria-targeted cationic antioxidants and analogs: Role of mitochondrial bioenergetics and energy-sensing mechanism. Cancer Lett. 2015 Aug 28;365(1):96-106. PMCID: PMC4476640 |
15. Zielonka J, Zielonka M, VerPlank L, Cheng G, Hardy M, Ouari O, Ayhan MM, Podsiadły R, Sikora A, Lambeth JD, Kalyanaraman B. Mitigation of NADPH Oxidase 2 Activity as a Strategy to Inhibit Peroxynitrite Formation. J Biol Chem. 2016 Mar 25;291(13):7029-44. PMCID: PMC4807286 |
16. Cheng G, Zielonka J, Ouari O, Lopez M, McAllister D, Boyle K, Barrios CS, Weber JJ, Johnson BD, Hardy M, Dwinell MB, Kalyanaraman B. Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells. Cancer Res. 2016 Jul 01;76(13):3904-15. PMCID: PMC4930686 |
17. Kalyanaraman B, Hardy M, Podsiadly R, Cheng G, Zielonka J. Recent developments in detection of superoxide radical anion and hydrogen peroxide: Opportunities, challenges, and implications in redox signaling. Arch Biochem Biophys. 2017 Mar 01;617:38-47. PMCID: PMC5318280 |
18. Kalyanaraman B, Cheng G, Hardy M, Ouari O, Sikora A, Zielonka J, Dwinell MB. Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies. Cell Biochem Biophys. 2017 Dec;75(3-4):311-317. PMCID: PMC5680142 |
19. Zielonka J, Hardy M, Michalski R, Sikora A, Zielonka M, Cheng G, Ouari O, Podsiadły R, Kalyanaraman B. Recent Developments in the Probes and Assays for Measurement of the Activity of NADPH Oxidases. Cell Biochem Biophys. 2017 Dec;75(3-4):335-349. PMCID: PMC5693611 |
20. Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB. A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds. Redox Biol. 2018 Apr;14:316-327. PMCID: PMC5633086 |
21. Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB. Corrigendum to 'A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds' [REDOX 14C (2017) 316-327]. Redox Biol. 2018 Jun;16:426-427. PMCID: PMC5952812 |
22. Kalyanaraman B, Cheng G, Hardy M, Ouari O, Sikora A, Zielonka J, Dwinell M. Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms. Interface Focus. 2017 Apr 06;7(2):20160109. PMCID: PMC5311906 |
23. Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, Cheng G, Lopez M, Kalyanaraman B. Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev. 2017 Aug 09;117(15):10043-10120. PMCID: PMC5611849 |
24. Kalyanaraman B, Cheng G, Hardy M, Ouari O, Bennett B, Zielonka J. Teaching the basics of reactive oxygen species and their relevance to cancer biology: Mitochondrial reactive oxygen species detection, redox signaling, and targeted therapies. Redox Biol. 2018 May;15:347-362. PMCID: PMC5756055 |
25. Pan J, Lee Y, Cheng G, Zielonka J, Zhang Q, Bajzikova M, Xiong D, Tsaih SW, Hardy M, Flister M, Olsen CM, Wang Y, Vang O, Neuzil J, Myers CR, Kalyanaraman B, You M. Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity. iScience. 2018 May 25;3:192-207. PMCID: PMC6137433 |
26. Cheng G, Zielonka M, Dranka B, Kumar SN, Myers CR, Bennett B, Garces AM, Dias Duarte Machado LG, Thiebaut D, Ouari O, Hardy M, Zielonka J, Kalyanaraman B. Detection of mitochondria-generated reactive oxygen species in cells using multiple probes and methods: Potentials, pitfalls, and the future. J Biol Chem. 2018 Jun 29;293(26):10363-10380. PMCID: PMC6028982 |
27. Boyle KA, Van Wickle J, Hill RB, Marchese A, Kalyanaraman B, Dwinell MB. Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation. J Biol Chem. 2018 Sep 21;293(38):14891-14904. PMCID: PMC6153299 |
28. Kalyanaraman B, Cheng G, Zielonka J, Bennett B. Low-Temperature EPR Spectroscopy as a Probe-Free Technique for Monitoring Oxidants Formed in Tumor Cells and Tissues: Implications in Drug Resistance and OXPHOS-Targeted Therapies. Cell Biochem Biophys. 2019 Mar;77(1):89-98. PMCID: PMC6430651 |
29. Cheng G, Zhang Q, Pan J, Lee Y, Ouari O, Hardy M, Zielonka M, Myers CR, Zielonka J, Weh K, Chang AC, Chen G, Kresty L, Kalyanaraman B, You M. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10(1):2205. PMCID: PMC6525201 |
30. Zielonka J, Zielonka M, Cheng G, Hardy M, Kalyanaraman B. High-Throughput Screening of NOX Inhibitors. Methods Mol Biol. 2019;1982:429-446. PMCID: PMC6953630 |
31. Cheng G, Zielonka J, Hardy M, Ouari O, Chitambar CR, Dwinell MB, Kalyanaraman B. Synergistic inhibition of tumor cell proliferation by metformin and mito-metformin in the presence of iron chelators. Oncotarget. 2019 May 28;10(37):3518-3532. PMCID: PMC6544408 |
32. Cheng G, Pan J, Podsiadly R, Zielonka J, Garces AM, Dias Duarte Machado LG, Bennett B, McAllister D, Dwinell MB, You M, Kalyanaraman B. Increased formation of reactive oxygen species during tumor growth: Ex vivo low-temperature EPR and in vivo bioluminescence analyses. Free Radic Biol Med. 2020 Feb 01;147:167-174. PMCID: PMC6948008 |
33. Zhang Q, Cheng G, Pan J, Zielonka J, Xiong D, Myers CR, Feng L, Shin SS, Kim YH, Bui D, Hu M, Bennett B, Schmainda K, Wang Y, Kalyanaraman B, You M. Magnolia extract is effective for the chemoprevention of oral cancer through its ability to inhibit mitochondrial respiration at complex I. Cell Commun Signal. 2020 Apr 07;18(1):58. PMCID: PMC7140380 |
34. Cheng G, Hardy M, Zielonka J, Weh K, Zielonka M, Boyle KA, Abu Eid M, McAllister D, Bennett B, Kresty LA, Dwinell MB, Kalyanaraman B. Mitochondria-targeted magnolol inhibits OXPHOS, proliferation, and tumor growth via modulation of energetics and autophagy in melanoma cells. Cancer Treat Res Commun. 2020;25:100210. PMCID: PMC7883397 |
35. Cheng G, Hardy M, Topchyan P, Zander R, Volberding P, Cui W, Kalyanaraman B. Potent inhibition of tumour cell proliferation and immunoregulatory function by mitochondria-targeted atovaquone. Sci Rep. 2020 Oct 21;10(1):17872. PMCID: PMC7578061 |
36. Cheng G, Hardy M, Topchyan P, Zander R, Volberding P, Cui W, Kalyanaraman B. Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects. iScience. 2021 Jun 25;24(6):102673. PMCID: PMC8215227 |
37. AbuEid M, McAllister DM, McOlash L, Harwig MC, Cheng G, Drouillard D, Boyle KA, Hardy M, Zielonka J, Johnson BD, Hill RB, Kalyanaraman B, Dwinell MB. Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression. iScience. 2021 Jun 25;24(6):102653. PMCID: PMC8220235 |
38. Cheng G, Hardy M, You M, Kalyanaraman B. Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation. Sci Rep. 2022 Mar 24;12(1):5143. PMCID: PMC8948292 |
39. Kalyanaraman B, Cheng G, Hardy M. Therapeutic Targeting of Tumor Cells and Tumor Immune Microenvironment Vulnerabilities. Front Oncol. 2022;12:816504. PMCID: PMC9214210 |
40. Cheng G, Karoui H, Hardy M, Kalyanaraman B. Polyphenolic Boronates Inhibit Tumor Cell Proliferation: Potential Mitigators of Oxidants in the Tumor Microenvironment. Cancers (Basel). 2023 Feb 08;15(4). PMCID: PMC9953882 |
41. Cheng G, Hardy M, Kalyanaraman B. Antiproliferative effects of mitochondria-targeted N-acetylcysteine and analogs in cancer cells. Sci Rep. 2023 May 04;13(1):7254. PMCID: PMC10160116 |
42. Cheng G, Karoui H, Hardy M, Kalyanaraman B. Redox-crippled MitoQ potently inhibits breast cancer and glioma cell proliferation: A negative control for verifying the antioxidant mechanism of MitoQ in cancer and other oxidative pathologies. Free Radic Biol Med. 2023 Aug 20;205:175-187. PMCID: PMC11129726 |
43. Kalyanaraman B, Cheng G, Hardy M, You M. OXPHOS-targeting drugs in oncology: new perspectives. Expert Opin Ther Targets. 2023;27(10):939-952. PMCID: PMC11034819 |
44. Kalyanaraman B, Cheng G, Hardy M. Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: Relevance to Parkinson's disease and therapeutic implications. Redox Biol. 2024 May;71:103092. PMCID: PMC10891329 |
45. Beerkens APM, Boreel DF, Nathan JA, Neuzil J, Cheng G, Kalyanaraman B, Hardy M, Adema GJ, Heskamp S, Span PN, Bussink J. Characterizing OXPHOS inhibitor-mediated alleviation of hypoxia using high-throughput live cell-imaging. Cancer Metab. 2024 May 03;12(1):13. PMCID: PMC11067257 |
46. Cheng G, Hardy M, Hillard CJ, Feix JB, Kalyanaraman B. Mitigating gut microbial degradation of levodopa and enhancing brain dopamine: Implications in Parkinson's disease. Commun Biol. 2024 May 30;7(1):668. PMCID: PMC11139878 |
47. Kalyanaraman B, Cheng G, Hardy M. The role of short-chain fatty acids in cancer prevention and cancer treatment. Arch Biochem Biophys. 2024 Nov;761:110172. PMCID: PMC11784870 |
48. Cheng G, Hardy M, Feix JB, Kalyanaraman B. Inhibition of levodopa metabolism to dopamine by honokiol short-chain fatty acid derivatives may enhance therapeutic efficacy in Parkinson's disease. Sci Rep. 2025 Jun 06;15(1):20004. PMCID: PMC12144245 |
49. Feix JB, Cheng G, Hardy M, Kalyanaraman B. Microbial Metabolism of Levodopa as an Adjunct Therapeutic Target in Parkinson's Disease. Antioxidants (Basel). 2026 Jan 17;15(1). PMCID: PMC12838373 |
